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Posttransplantation thrombotic microangiopathy (TMA) is a multifactorial complication of allogeneic
hematopoietic cell transplantation (allo-HCT) whose incidence is increased with the use of a sirolimus plus
tacrolimus (SIR/TAC) regimen for acute graft-versus-host disease (aGVHD) prophylaxis. We evaluated the
incidence and possible risk factors for TMA in a case series of 177 patients who received allo-HCT using SIR/
TAC-based GVHD prophylaxis. The patients received either a sibling donor graft (n ¼ 82) or a matched
unrelated donor graft (n ¼ 95). Within the ﬁrst 100 days post-HCT, 30 patients (17%) were diagnosed with
TMA, and an additional 9 patients (5%) were classiﬁed as probable TMA cases. The median time to onset of
TMA was 4.6 weeks (range, 1.6-10.6 weeks). Thirty-four patients developed both TMA and aGVHD, with the
majority (81%) developing aGVHD ﬁrst. Multivariate analysis identiﬁed the following factors as associated
with increased risk of TMA: day 14 serum sirolimus level 9.9 ng/mL (hazard ratio [HR], 2.19; 95% conﬁdence
interval [CI], 1.13-4.27; P ¼ .02), presence of previous aGVHD grade II-IV (HR, 3.04; 95% CI, 1.38-6.71; P < .01),
and fully myeloablative conditioning (HR, 3.47; 95% CI, 1.60-7.53; P < .01). These risk factors for TMA suggest
that when using a SIR/TAC regimen for GVHD prophylaxis, careful monitoring and adjustment of the sirolimus
dosage is critical, particularly in patients with active aGVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Blood and Marrow Transplant Clinical Trials Network (BMT
Posttransplantation thrombotic microangiopathy (TMA)
is a serious complication of hematopoietic stem cell trans-
plantation (HCT), characterized by the presence of arteriolar
thrombi associated with damaged vessel walls. These
thrombi lead to intravascular platelet activation and
formation of platelet-rich thrombi within the microcircula-
tion, causing platelet consumption, mechanical damage to
blood cells, and organ damage [1]. Post-HCT TMA has
been attributed to the vascular endothelial damage caused
by radiation therapy, high-dose chemotherapy, immuno-
suppressive agents, graft-versus-host disease (GVHD), or
infections [2]. Unlike most cases of familial or acquired
thrombotic thrombocytopenic purpura, bone marrow
transplantationeassociated TMA is not generally associated
with severely reduced or absent plasma metalloprotease
ADAMTS13 activity [3]. With a few exceptions, plasma
exchange is ineffective in treating TMA [3].
Diagnosing TMA in HCT recipients has proven chal-
lenging, owing to the presence of multiple contributing
factors including opportunistic infections, delayed engraft-
ment, medications, regimen-related toxicity, presence of
acute GVHD (aGVHD), and other disorders associated with
the HCT process. In 2005, the Toxicity Committee of theedgments on page 303.
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12.10.006CTN) proposed an operational deﬁnition of TMA (Table 1).
Subsequently, an International Working Group was formed
to develop a consensus set of criteria for diagnosing
TMA [4] (Table 1).
Calcineurin inhibitors, such as cyclosporine and tacroli-
mus, may contribute to the development of TMA by
increasing the production of thromboxane A2 and decreasing
production of prostacyclin, as well as by directly damaging
renal endothelial cells. These agents also can cause neuro-
toxicity, another feature of TMA [1,2,5]. Recent studies have
demonstrated that adding sirolimus to calcineurin inhibitors
increases the risk of TMA after HCT [6,7]. The etiology of
sirolimus-induced TMA is not clear, but may be related to
enhanced platelet activation and aggregation, leading to
endothelial damage. Another theory involves the pharma-
cokinetic interaction between sirolimus and calcineurin
inhibitors, which might lead to increased serum and kidney
levels of these agents.
In the present retrospective analysis, we sought to extend
our earlier observations [7] and determine the incidence and
clinical characteristics of post-HCT TMA associated with
sirolimus and tacrolimus (SIR/TAC)-based GVHD prophylaxis.
In addition, we evaluated the association between TMA and
SIR/TAC serum levels in detail.PATIENTS AND METHODS
Study Design
Between January 2005 and August 2007, a consecutive case series of
177 patients underwent allogeneic HCT (allo-HCT) at City of Hope usingTransplantation.
Table 1
Diagnostic Criteria for TMA
Criterion City of Hope* CIBMTR BMT CTN International Working Group
Hemolysis Presence of schistocytes,
persistent nucleated RBCs
Microangiopathic hemolysis RBC fragmentation and 2
schistocytes/high-power ﬁeld
on peripheral smear; negative
direct and indirect Coombs test
Presence of (>4%) schistocytes
in the blood; decreased
haptoglobin or increased RBC
transfusion requirement
Thrombocytopenia Prolonged or progressive
thrombocytopenia (platelets
<50  109/L or 50% decrease
from previous counts)
Thrombocytopenia (platelets
<50  109/L)
Prolonged or progressive
thrombocytopenia (platelets
<50  109/L or 50% decrease
from previous counts)
Liver function LDH >2 times upper limit of
normal
LDH >2 times upper limit
normal; bilirubin <2 times
upper limit of normal
Concurrent increase in LDH
above institutional baseline
Sudden, persistent increase in
LDH
Renal function SCr >1.5 times baseline SCr >2 mg/dL or >50% over
baseline
Concurrent renal and/or
neurologic dysfunction with no
other explanation
Neurologic Neurologic changes Concurrent renal and/or
neurologic dysfunction with no
other explanation
CIBMTR indicates Center for International Blood and Marrow Transplant Research; LDH, lactate dehydrogenase.
* The presence of all 4 City of Hope criteria listed deﬁnes deﬁnite TMA. Probable TMA is deﬁned as concomitant presence of 3 of the 4 criteria in the presence of
clinical diagnosis by an independent attending physician.
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from either a matched related sibling or a matched unrelated donor (MUD).
Patients were identiﬁed and selected for retrospective analysis from
a prospective observational research database. The City of Hope Institutional
Review Board approved the analysis of these data. The patients with
a matched related donor were previously reported as part of a phase I/II
study [7].
Conditioning and GVHD Prophylaxis Regimens
Conditioning regimens included ﬂudarabine (Flu)/melphalan (Mel)in
106 patients (59.9%), fractionated total body irradiation (FTBI)/cyclophos-
phamide (Cy) in 11 patients (6.2%), FTBI/etoposide in 46 patients (26.0%),
and busulfan (Bu)/Cy in 14 patients (7.9%). Of these regimens, only Flu/Mel
was classiﬁed as a reduced-intensity regimen. Patients were selected for
a reduced-intensity regimen based on advanced age or the presence of other
comorbidities in accordance with institutional protocol. GVHD prophylaxis
was administered as described previously [7,8], as follows: sirolimus 12 mg
orally on day 3 (loading dose), followed by 4 mg/day orally, with subse-
quent dose adjustments to maintain serum level at 3-12 ng/mL. Tacrolimus
was initially dosed at 0.02 mg/kg/day i.v. starting on day 3, then switched
to an equivalent oral dose when oral intake was adequate, to maintain
a target serum level of 5-10 ng/mL. Serum sirolimus and tacrolimus levels
were measured at least weekly until day þ100, with dosage adjustments
made for target levels and/or clinical toxicity. For MUD HCT with a <10/10
HLA-matched donor, methotrexate 5 mg/m2 was added on days þ1, þ3,
and þ6. One patient undergoing MUD-HCT also received antithymocyte
globulin 0.5 mg/kg on day 3, 1.5 mg/kg on day 2, and 2.5 mg/kg on
day 1.
Supportive Care
Supportive care, including prophylactic antibiotics, antifungals, total
parenteral nutrition, hematopoietic growth factors, immune globulin
replacement, and treatment of mucositis and neutropenic fever, was
administered in accordance with institutional protocols. All patients
received acyclovir 250 mg/m2 starting on day 1. Antifungal prophylaxis
consisted of low-dose lipid complex amphotericin B (Abelcet; 1 mg/kg),
caspofungin, or micafungin starting on day 0 or day þ1. In addition, an oral
azole antifungal (eg, posaconazole, voriconazole, ﬂuconazole, itraconazole)
was later added in selected patients for prophylaxis or treatment of fungal
infections. Sinusoidal obstructive syndrome (SOS) prophylaxis was provided
with low-dose heparin (100 U/kg/day) or ursodiol 300 mg twice daily.
Deﬁnition of TMA
We evaluated patients for TMA based on the criteria used at City of
Hope. Our criteria are compared with other commonly used criteria in
Table 1. Patients were diagnosed with deﬁnite TMA if theymet the following
diagnostic criteria: increased serum creatinine (sCr) level 50% above
baseline, lactate dehydrogenase >2 times the upper limit of normal, the
presence of schistocytes or persistent presence of nucleated RBCs, and
prolonged or progressive thrombocytopenia (<50 x 109/L or  50%
decrease). Patients were classiﬁed as having probable TMA if theyexperienced 3 of the 4 aforementioned criteria. Patients with characteristics
of TMA secondary to disease relapse or progression were not classiﬁed as
TMA cases in this study.
Deﬁnitions of GVHD and Response to Intervention
aGVHD was deﬁned and staged according to Glucksberg et al. [9].
Chronic GVHD (cGVHD) was deﬁned and staged by the limited/extensive
classiﬁcation scheme [10]. The response of TMA to intervention was deﬁned
as follows: complete response (CR), resolution of all TMA criteria to patient
baseline; partial response (PR), improvement in individual TMA criteria such
that the patient no longer meets the deﬁnition of TMA but has not returned
to baseline levels.
Statistical Analysis
Demographic, disease, and treatment characteristics were summarized
using descriptive statistics. Survival estimates were calculated based on the
Kaplan-Meier product-limit method [11]; 95% conﬁdence intervals (CIs)
were calculated using the logit transformation and the Greenwood variance
estimate [12]. Differences between Kaplan-Meier curves were assessed
using the log-rank test. Patients who were alive at the time of analysis were
censored at the last contact date. Overall survival (OS) was measured from
transplantation to death from any cause. Event-free survival (EFS) was
deﬁned as the time from transplantation to disease recurrence, disease
progression, or death. The relapse/progression incidence was deﬁned as
time from transplantation to disease recurrence or progression. The
cumulative incidence of relapse/progression was computed treating a non-
relapse death event as a competing risk, as described by Gooley et al. [13].
Nonrelapsemortality (NRM)wasmeasured from the time of transplantation
to death from any cause other than disease relapse or progression. The
cumulative incidence of NRM was calculated using relapse/progression
incidence as a competing risk. The cumulative incidence of aGVHD and
hazard ratio (HR) were estimated after taking into account the competing
risk of engraftment failure and early death/relapse. Time to onset of cGVHD
was estimated accounting for the competing risks of early death or second
transplant. Similarly the cumulative incidence of TMA was estimated after
accounting for the competing risk of death and relapse. Possible differences
between cumulative incidence curves in the presence of a competing risk
were tested using the Gray method [14]. The signiﬁcance of disease and
treatment features on TMA risk and on NRM risk was assessed using the Cox
proportional hazards regression analysis competing risks analogue [15].
In addition, a joint model [16] of tacrolimus/sirolimus serum levels and
time to TMAwas examined to consider the shared evolution of the repeated
drug level measurements and event times, when a possible association
between the two processes exists. Square-root transformed sirolimus and
tacrolimus serum levels were used to reduce the variability of individual
measurements and improve normality of the data. A desirable feature of the
joint modeling approach is that when an association is absent, the joint
analysis will produce the same results as would be obtained by performing
separate analyses for each process.
An exploratory “drug level” analysis was also performed using the
calculated median values for both tacrolimus and sirolimus levels over set
durations (7, 14, and 30 days) post-HCT for each patient. For example, the
Table 2
Patient, Disease, and Transplantation Characteristics (n ¼ 177)
Variable Value
Patient sex, n (%)
Female 79 (44.6)
Male 98 (55.4)
Patient/donor sex match, n (%)
Male/female 40 (22.6)
Others 137 (77.4)
Age at transplantation, years, median (range) 46 (10-70)
Disease risk status at transplantation, n (%)*
Low risk 69 (39.0)
Intermediate risk 33 (18.6)
High risk 75 (42.4)
Diagnosis, n (%)
Acute myelogenous leukemia 63 (35.6)
Acute lymphoblastic leukemia 39 (22.0)
Non-Hodgkin lymphoma 25 (14.1)
Myelodysplastic syndrome 17 (9.6)
Chronic myelogenous leukemia 9 (5.1)
Myeloproliferative disorder 9 (5.1)
Hodgkin’s lymphoma 8 (4.5)
Multiple myeloma 4 (2.2)
S. Shayani et al. / Biol Blood Marrow Transplant 19 (2013) 298e304300day 14 sirolimus level was the median value for the patient over the 14 days
post-HCT (twice weekly levels, so 4 levels). Based on our published SIR/TAC
experience, as part of a phase II trial using sibling donors, we hypothesized
that SIR/TAC serum levels in the early period post-alloHCT (ﬁrst 30 days)
would be the most predictive of TMA outcome, even for those patients who
maintain serum levels considered therapeutic/nontoxic. Thus, we con-
ducted serum level evaluations for modeling at days 7, 14, and 30 days,
among the upper quartiles of each of the distributions (equal to or greater
than median values) for both tacrolimus and sirolimus.
TMA endpoints (eg, deﬁnitive, deﬁnitive/probable) were modeled as
a function of prognostic variables that were determined by a literature
review identifying factors associated with development of TMA in patients
treated with allo-HCT. Factors evaluated for association with outcome
included patient age at transplantation (<46 or 46 years), patient/donor
sex match (female donor to male patient; others), disease risk status at
transplantation (low, intermediate, or high; deﬁned in Table 2), patient/
donor cytomegalovirus status, conditioning regimen (Flu/Mel, FTBI/etopo-
side or Cy, or Bu/Cy; reduced intensity ormyeloablative), donor type (related
or unrelated), and aGVHD grade (0-I or II-IV). aGVHD grade II-IV was treated
as a time-dependent covariate in the risk factor analysis for TMA. All
calculations were performed using SAS version 9.2 (SAS Institute, Cary, NC)
and R version 2.11.1 (http://www.r-project.org). Statistical signiﬁcance was
set at the P < .05 level; all P values were 2-sided. The data were locked for
analysis on July 31, 2010 (analytic date).Chronic lymphocytic leukemia 3 (1.7)
Donor, n (%)
Sibling 82 (46.3)
Unrelated 95 (53.7)
Stem cell source, n (%)
Bone marrow 23 (13.0)
Peripheral blood 154 (87.0)
Cytomegalovirus serostatus, n (%)
Patient-positive/donor-positive 75 (42.4)
Patient-positive/donor-negative 51 (28.8)
Patient-negative/donor-positive 25 (14.2)
Patient-negative/donor-negative 26 (14.7)RESULTS
This study comprises a consecutive case series of 177
patients who underwent allo-HCT at City of Hope between
January 2005 and August 2007. Eighty-two patients (46%)
received stem cells from a sibling donor, and 95 patients
underwent matched unrelated HCT. The median patient age
was 46 years (range, 10-70 years). Patient, disease, and
transplantation characteristics are summarized in Table 2.Conditioning regimen, n (%)y
Flu/Mel 106 (59.9)
FTBI/Cy 11 (6.2)
FTBI/etoposide 46 (26.0)
Bu/Cy 14 (7.9)
* Disease risk status categories: low risk, all diseases in ﬁrst complete
remission, myeloma in partial remission, chronic myelogenous leukemia
(CML) in ﬁrst chronic phase, refractory anemia, and refractory anemia with
ringed sideroblasts; intermediate risk, lymphoma/leukemia in second
complete remission or partial remission, CML in second chronic phase or
accelerated phase, myeloproliferative disorders; high risk, all diseases in
relapse, induction failure or progressive disease, CML blast crisis, refractory
anemia with excess blasts.
y Of the conditioning regimens, only Flu/Mel was reduced intensity; all
others were fully myeloablative.Overall HCT Outcomes
At a median follow-up of 50 months, 89 patients (49.5%)
were alive. Of the 88 patient deaths, 42 were due to disease
relapse/progression, and the remaining 46 were due to
nonerelapse-related causes. The median time to neutrophil
engraftment was 16 days; 4 patients failed to engraft. The OS,
EFS, and cumulative incidence of relapse/progression at 2
years were 59.9% (95% CI, 55.4%-64.1%), 51.7% (95% CI, 47.8%-
55.5%), and 31.1% (95% CI, 25.0%-38.7%), respectively. NRM
was 7.4% (95% CI, 4.4%-12.4%) at 100 days and 15.8% (95% CI,
11.3%-22.2%) at 2 years. The cumulative incidence of aGVHD
grade II-IV was 50.5% (95% CI, 43.2%-59.1%), with a median
onset of 23 days (Figure 1A). The cumulative incidence of
grade III-IV aGVHD was 17.9% (95% CI, 10.6%-30.2%). The
cumulative incidence of cGVHD (ie, time to cGVHD with
competing risks of early death or second transplantation)
was 62.5% (95% CI, 55.6-70.3%) at 1 year and 71.3% (95% CI,
64.6-78.7%) at 2 years.Incidence and Timing of TMA
TMA data are summarized in Table 3. Of the 177 patients
studied, 30 (17%) were diagnosed with deﬁnite TMA based
on the institutional diagnostic criteria. In addition, 9 patients
did not meet the deﬁnitive diagnostic criteria owing to
a missing test, but were clinically diagnosed with TMA by an
independent attending physician (ie, probable TMA). If those
patients with probable TMA were included, the overall
incidence of TMA in this study would be 22% (39 of 177)
(Figure 1B). Seven of these 39 patients (17.5%) met the
criteria for deﬁnitive/probable TMA in the setting of ongoing
multiorgan failure. The median time from HCT to onset of
deﬁnite TMA was 4.6 weeks (range, 1.6-10.6 weeks). TMA
outcomes are presented in Table 3.Management of TMA and Outcomes
TMA interventions and responses are detailed in Table 4.
Initial treatment for patients diagnosed with deﬁnite TMA
(n ¼ 30) included discontinuation of sirolimus (n ¼ 9),
tacrolimus (n ¼ 8), or both (n ¼ 6) and immunosuppressant
dosage adjustments for the remaining 7 patients. At the time
of resolution, tacrolimus and sirolimus were both dis-
continued in 12 patients, and only 4 patients remained on
the combination. Sirolimus alone was continued for 11
patients, whereas tacrolimus alone was continued in only 3
patients. Of the 30 patients diagnosed with TMA, 8 were
treated with plasma exchange at the discretion of the
treating physician, and 4 of these patients responded. Over-
all, 22 patients (73%) responded to treatment, with
a complete resolution rate of 70%. The median time from
diagnosis of TMA to response and resolution of symptoms
was 4.5 and 5.5 weeks, respectively (range, 1-27 weeks).
Twenty-ﬁve patients had both tacrolimus and sirolimus
discontinued and were managed with mycophenolate
mofetil (MMF) plus prednisone (n ¼ 15), prednisone alone
(n ¼ 9), or MMF alone (n ¼ 1). One patient was discontinued
from sirolimus but remained on tacrolimus alone.
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Figure 1. Cumulative incidence of aGVHD and TMA in the ﬁrst 100 days
posttransplantation. (A) Time to onset of grade II-IV aGVHD. (B) Time to onset
of deﬁnitive TMA, with death before 100 days calculated as a competing risk.
Table 4
Response of TMA to SIR/TAC Intervention
Intervention Initial
Intervention
Final
Intervention
Discontinued sirolimus, responded/
treated
9/9 11/11
Discontinued tacrolimus, responded/
treated*
5/8 3/3
Discontinued tacrolimus and sirolimus,
responded/treatedy
2/6 5/12
Dosage modiﬁcation, responded/
treated*
6/7 3/4
Values are the number of patients responding to a treatment over the
number treated. The initial intervention shows the ﬁrst treatment responses
in each category; ﬁnal intervention, results of the last treatment attempted.
* One patient was treated with dosage reduction of sirolimus and
discontinuation of tacrolimus and plasma exchange, and responded to this
therapy.
y Seven patients were treated with discontinuation of both tacrolimus
and sirolimus as well as plasma exchange, and 3 patients responded to this
overall therapy.
NRM stratified by TMA
P = 0.004
1.0
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TMA and those without TMA. The cumulative incidence of
NRM at 2 years was 33.3% in those with TMA, compared
with 12.25% in those without TMA (P ¼ .004) (Figure 2).
According to the multivariate model for NRM, after adjustingTable 3
TMA Outcomes
Variable (n ¼ 30 for Deﬁnite TMA) Value
TMA incidence, % 17 (30 of 177 patients)
Time to TMA onset, weeks, median
(range)
4.6 (1.6-10.6)
TMA with aGVHD (any time), % 90 (27 of 30 TMA cases)
TMA with previous aGVHD, % 81 (22 of 27 cases with aGVHD)
TMA response to treatment
Response, % 73 (22 of 30 TMA cases)
Time to response, weeks, median 4.5 (1-27)
Complete resolution, % 70 (21 of 30 TMA cases)
Time to complete resolution,
weeks, median (range)
5.5 (1-27)
Maximum LDH 1128-62,817
Median LDH 2230
Maximum creatinine 0.6-4.5
Median creatinine 1.5for conditioning regimen, aGVHD, and serum sirolimus level,
TMAwas independently associated with increased NRM (HR,
2.76; 95% CI, 1.29-5.92; P ¼ .009). Multivariate results for
NRM are summarized in Table 5.
Acute GVHD and Use of Azoles in Patients with TMA
The overall cumulative incidence of aGVHD (grade II-IV)
was 50.5% (95% CI, 43.2%-59.1%). Among the 30 patients
who developed deﬁnite TMA, 27 (90%) also developed
aGVHD, with the majority (81%) developing TMA after
aGVHD had been diagnosed. Of the 30 patients with deﬁni-
tive TMA, 14 did not receive an azole, 15 received an azole
(3 posaconazole in 3, itraconazole in 5, and voriconazole in 7)
before TMA was diagnosed, and 1 received voriconazole at
the time of TMA diagnosis.
High Sirolimus Level Associated with TMA
Factors identiﬁed on univariate Cox regression analysis
as signiﬁcantly associated with TMA at the P ¼ .10
leveldconditioning regimen, presence of aGVHD, serum
sirolimus level at day þ14dwere included in theTMA
no TMA
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Figure 2. NRM stratiﬁed by presence of TMA. Time to death from nonrelapse
causes calculated with relapse, progression, or second transplantation as
competing risks. The dashed line represents patients with deﬁnitive TMA
(based on laboratory criteria).
Table 5
HR for Risk of NRM and TMA
Parameter Value No. of Patients No. of Events HR (95% CI) P Value
NRM risk
Sirolimus, 14-day level, ng/mL <9.9 132 21 Baseline
9.9 44 12 1.67 (0.79-3.51) .18
TMA No TMA 146 22 Baseline
Deﬁnitive TMA 30 11 2.76 (1.29-5.92) .009
TMA risk
Conditioning Reduced intensity 106 9 Baseline
Fully myeloablative 70 21 3.47 (1.60-7.53) .002
aGVHD Grade 0-I 95 8 Baseline
Grade II-IV 81 22 3.04 (1.38-6.71) .006
Sirolimus, 14-day level, ng/mL <9.9 131 18 Baseline
9.9 45 12 2.19 (1.13-4.27) .02
Reduced-intensity conditioning included only the Flu/Mel regimen; all other regimens were fully myeloablative.
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displayed in Table 5. The highest quartile of serum sirolimus
exposure on day 14 (cutoff, 9.9 ng/mL) was found to be
independently associated with an increased risk of deﬁnitive
TMA (HR, 2.19, 95% CI, 1.13-4.27; P ¼ .02). Other signiﬁcant
risk factors were previous aGVHD grade II-IV and use of
a fully myeloablative conditioning regimen (Table 5). Tacro-
limus levels were not signiﬁcantly associated with TMA.
Median drug levels over the ﬁrst 30 days after allo-HCT were
not found to be predictive of TMA overall.
Because sirolimus binds to the same family of intracel-
lular FK-506 (tacrolimus)-binding proteins at a site distinct
from tacrolimus, these 2 drugs may interact or, when used in
combination, produce a total effect greater than the sum of
their individual effects. We further evaluated the possible
impact of tacrolimus and sirolimus levels on TMA risk by
constructing joint models of the repeated drug level
measurements over time and time-to-event (TMA) data. The
joint models included both additive (model 1) and multi-
plicative (model 2) parameters for sirolimus and tacrolimus
(SIR þ TAC, SIR  TAC), with and without other covariates
(eg, age, type of conditioning regimen). The additive
joint model showed a marginally signiﬁcant drug-level
effect (association, P ¼ .06 for deﬁnite TMA; Supplemental
Table 1), suggesting that TMA risk also might be affected by
the additive effects of the 2 drugs beyond the individual
effects of sirolimus, as demonstrated on multivariate anal-
ysis. This marginal signiﬁcance remained after adjusting for
other covariates, age, and conditioning regimen (P ¼ .07 for
deﬁnite TMA; Supplemental Table 2). The results of the joint
multiplicative model were not signiﬁcant.
DISCUSSION
Our data extend earlier observations, including those
from City of Hope and Dana-Farber Cancer Institute, that SIR/
TAC-based GVHD prophylaxis is associated with an increased
risk of TMA. With increased numbers of patients and more
detailed drug level analysis, our data corroborate that serum
sirolimus level is one of the risk factors associated with TMA.
Diagnosis of TMA is difﬁcult in patients who have
undergone HCT, who commonly develop thrombocytopenia,
anemia, renal dysfunction, and RBC fragmentation post-
transplantation [17]. Schistocytes occur in a variety of
conditions, including chronic renal failure, preeclampsia, and
prosthetic heart valve implantation. The presence of up to 4%
schistocytes in the absence of other TMA hallmarks also has
been reported in patients receiving marrow allografts or
autografts for various indications, which puts these patients
at risk for misdiagnosis of TMA [3]. Cho et al. [18] validatedcriteria for TMA proposed by the BMT CTN [17] and the
International Working Group (IWG) [4], in an analysis of 672
allogeneic HCT recipients. In their study, the incidence of
TMA by BMT CTNedeﬁned criteria was 6.1%, compared with
an incidence of only 2.5% by the IWG deﬁnition. These
authors reported an overall cumulative incidence of TMA of
12.7%, which included both deﬁnite TMA cases (by BMT CTN
criteria) and probable TMA cases (meeting BMT CTN criteria
without renal or neurologic dysfunction). Two-thirds of the
patients deﬁned as having TMA by the BMT CTN criteria had
no schistocytes, which is required by the IWG criteria, and
18% of the patients classiﬁed with TMA based on the IWG
criteria did not have renal or neurologic dysfunction.
In the present study, we used institutional criteria for
TMA (Table 1). We did not set a quantitative criterion for
schistocytes, because precise quantiﬁcation is difﬁcult, and
the presence of any schistocytes in the setting of hemolysis is
considered sufﬁcient to indicate suspected TMA. To capture
a broad range of TMA or TMA-like pathology, we included
nucleated RBCs as part of our TMA assessment, given our
impression that nucleated RBCs tend to appear earlier than
schistocytes and are more readily detected on routine CBC
analyses. The vast majority (93%) of our patients with TMA
presented with both nucleated RBCs and schistocytes. In our
analysis, we also considered probable cases in which there
was one missing test/criterion and/or the treating physician
made a clinical diagnosis of TMA and intervened accordingly.
Although we report results only for the deﬁnite TMA cases,
we conducted all of the analyses including the probable TMA
cases as well, and found qualitatively similar results. We
included the probable cases because we believe that TMA is
often underestimated in the literature. For example, at our
institution, many probable cases were identiﬁed as TMA by
the treating physician before the patient met all 4 criteria, to
allow for earlier institution of treatment in a “preemptive
strike” approach.
Recent studies, including our own study, have demon-
strated a particularly high incidence of TMA after allo-HCT
using sirolimus-containing GVHD prophylaxis [6-8]. Our
present ﬁndings conﬁrm and extend the previous results and
more closely associate TMA with higher serum sirolimus
levels, even levels believed to be therapeutic and nontoxic.
Importantly, signiﬁcant associations with sirolimus serum
levels >9.9 ng/mL were observed for the early time points
(posttransplantation day 14). Based on these data, we have
modiﬁed our upper range of therapeutic sirolimus levels
from the original 12 ng/mL to 10 ng/mL. Although our
present analysis identiﬁed no direct impact of tacrolimus on
TMA, computing tacrolimus levels together with sirolimus
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a trend toward an association with TMA (P ¼ .07 by multi-
variate analysis). In other words, tacrolimus when given in
combination with sirolimus may increase the risk of TMA
beyond that associated with sirolimus alone. This issue
merits additional study with a larger number of patients.
Serum levels of both tacrolimus and sirolimus are also
inﬂuenced by genes affecting drug absorption, distribution,
metabolism, and excretion (ADME). Allelic variants in ADME
genes can determine the pharmacokinetic variability of
medications and have been shown to inﬂuence the outcomes
of medical treatments using these drugs for kidney trans-
plantation. We are currently investigating the effects of
ADME variants in HCT recipients with the goal of better
tailoring the initial doses of these drugs to avoid toxicities,
including TMA.
We also identiﬁed other TMA risk factors, including fully
myeloablative conditioning regimens and previous occur-
rence of aGVHD grade II-IV. Concurrent GVHD has been re-
ported as a risk factor by the Dana-Farber Cancer Institute [6]
and others [19]. Bu/Cy conditioning has been previously
associated with TMA and SOS, but we found no independent
association of Bu/Cy with incidence of TMA. Rather, fully
myeloablative conditioning was independently signiﬁcantly
associated with TMA, even when patients receiving Bu/Cy
were excluded from the analysis. The addition of metho-
trexate to sirolimus has been shown to increase the risk of
SOS [20]. In the present study, all recipients of MUD grafts
received methotrexate, yet there was no signiﬁcant differ-
ence in the incidence of TMA between recipients of sibling
donor grafts and recipients of MUD donor grafts in this
cohort of patients. Patients who developed TMA demon-
strated an independently signiﬁcant increased risk of NRM,
highlighting the need to better understand and prevent this
complication of HCT.
A potential risk factor that we would like to pursue in
a prospective study is the role of previous azole antifungal
agents. Given this study’s retrospective nature, detailed
data on azole use were not collected for all patients, but
they were obtained for the TMA cases. Half of the patients
with deﬁnitive TMA had previous exposure, which is high
for our practice, in which primary prophylaxis includes
nonazole antifungal medications. Because azoles are
commonly used for patients with GVHD requiring high-
dose steroids, an independent effect of azoles is difﬁcult
to analyze; thus, we opted to exclude this factor in our Cox
model.
There are no standardized treatments for post-HCT TMA.
Given that plasma exchange has not been shown to provide
a signiﬁcant beneﬁt in treating patients with TMA and is
associated with major complications [21], most patients
were not treated with this modality. Discontinuation of
tacrolimus and/or sirolimus was the primary means of
treatment for TMA and three-quarters of the patients
improved in this study. However, survival outcomes were
signiﬁcantly different between those who developed TMA
and those who did not (Figure 2). In the majority of patients
who died without relapse after experiencing TMA, the cause
of death was associated with GVHD/infection, many of which
met the deﬁnition of TMA in the context of multiorgan
failure. Thus, based on the present study, it cannot be
concluded that the occurrence of TMA is an independent
predictor of poor survival.
Our data should be interpreted with caution. The
observed associations between sirolimus levels and TMAmay be related to hidden confounding factors in this
heterogeneous cohort. Although sirolimus levels were
checked at trough levels and in a consistent manner in our
program, there is inherent variability in the exact timing of
the blood draws and patients’ compliance with instructions
in an outpatient setting. To minimize this variability, we
focused our multivariate analysis on the early post-HCT
period (within 30 days), during which most drug level
measurements were obtained in the inpatient setting. Our
data indicate a doseeresponse relationship between the use
of sirolimus and the occurrence of TMA, and suggest that SIR/
TAC therapy may exacerbate this effect. The currently
accepted sirolimus therapeutic ranges may be too high,
contributing to unacceptable toxicity in some patients,
particularly those with concurrent GVHD or a genetic
predisposition based on ADME genes.
Our institutional guidelines have been modiﬁed to
maintain both sirolimus and tacrolimus levels in the
5-10 ng/mL range whenever they are used in combination.
We previously allowed 3-12 ng/mL for sirolimus, but have
amended this range based on data from the present study
and work by Rodriguez et al. [7]. In addition, in the event of
fungal infection, if azoles are used, we recommend dosage
reduction of tacrolimus and sirolimus to prevent supra-
therapeutic levels secondary to drugedrug interaction. For
patients with active GVHD who develop TMA, based on the
severity of TMA, we recommend dosage adjustment or
discontinuation of sirolimus or of both sirolimus and tacro-
limus. Other immunosuppressive agents, such as steroids
andmycophenolate mofetil, are typically used in the event of
discontinuation.
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